<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581113</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-10655</org_study_id>
    <nct_id>NCT00581113</nct_id>
  </id_info>
  <brief_title>Neural Stem Cell Preserving Brain Radiation Therapy &amp; Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases</brief_title>
  <official_title>A Study of Neural Stem Cell (NSC) Preserving Whole Brain Radiation Therapy (WBRT) and Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with 1-6 intraparenchymal brain metastases from various primary histologies
      (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or
      complete surgical resection with neural stem cell (NSC)-preserving whole-brain radiotherapy
      (WBRT) results in improved neurocognitive profile over standard WBRT. The goal of this study
      is to assess feasibility of this treatment approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer patients (except patients with melanoma) with 1-6 brain metastases are randomized to
      receive standard whole brain radiation therapy or whole brain radiation therapy in a neural
      stem cell-preserving manner.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New research priorities
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in the Bi-dimensional Tumor Area for Any of the Tracked Brain Metastases or the Appearance of Any New Brain Metastases on a Follow-up MRI.</measure>
    <time_frame>12 months post RT</time_frame>
    <description>Brain metastases bi-dimensional area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in the Bi-dimensional Tumor Area for Any of the Tracked Brain Metastases or the Appearance of Any New Brain Metastases on a Follow-up MRI.</measure>
    <time_frame>12 months after end of radiation therapy</time_frame>
    <description>Increase in the bi-dimensional tumor area for any of the tracked brain metastases or the appearance of any new brain metastases on a follow-up MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Whole Brain Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neural Stem Cell-Preserving Whole Brain Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-melanoma primary malignancy with 1-6 intraparenchymal
             brain metastases (or small cell lung cancer being considered for prophylactic brain
             irradiation (PBI) with no demonstrable intracranial lesions).

          -  A diagnostic contrast-enhanced magnetic resonance imaging (MRI) demonstrating the
             presence of 1-6 brain metastases performed within 4 weeks of registration. Note: If
             small cell lung cancer primary and patient being considered for PBI, MRI must
             demonstrate no intracranial lesions.

          -  Patients with totally resected intraparenchymal brain metastases; not all lesions need
             be resected if all other criteria are satisfied (no more than 6 total lesions)

          -  The contrast-enhancing intraparenchymal brain tumor must be well circumscribed and
             must have maximum diameter of no more than 4 cm in any dimension on the enhanced scan.
             If multiple lesions are present and one lesion is at the maximum diameter, the
             other(s) must not exceed 3.0 cm in maximum diameter.

          -  Metastatic lesions must be distributed peripherally, that is, at least 0.5 cm lateral
             (outside) of the lateral ventricles and/or hippocampus bilaterally. Posterior fossa
             metastatic lesions are allowed in the study.

          -  Age 18 years or older.

          -  Zubrod performance score 0-1.

          -  Neurologic function score 0, 1, or 2.

          -  Patients receiving glucocorticoids should be tapered to the lowest possible dose, or
             altogether, as judged by the participating physician. If glucocorticoid dose is
             adjusted or given for the first time, patient must remain on stable dose of
             glucocorticoids for at least 3 days prior to initial Neurocognitive Assessment
             Protocol (NAP), CT and MR imaging.

        Exclusion Criteria:

          -  Major medical illnesses or psychiatric impairments, which in the investigators opinion
             will prevent administration or completion of the protocol therapy and/or interfere
             with follow-up.

          -  For patients who have undergone subtotal resection, residual disease must be 4 cm in
             maximum diameter.

          -  Inability to obtain histologic proof of primary malignancy.

          -  Patients with leptomeningial metastases documented by MRI or cerebral spinal fluid
             (CSF) evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S. Anscher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massey Cancer Center/Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <results_first_submitted>October 6, 2010</results_first_submitted>
  <results_first_submitted_qc>January 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2011</results_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>whole brain radiotherapy</keyword>
  <keyword>neural stem cell</keyword>
  <keyword>brain metastases</keyword>
  <keyword>radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 08/2007 through 07/2008 in Radiation Oncology clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Neural Stem Cell-Preserving Whole Brain RT</title>
          <description>Neural Stem Cell-Preserving Whole Brain Radiotherapy</description>
        </group>
        <group group_id="P2">
          <title>Standard Whole Brain RT</title>
          <description>Standard Whole Brain Radiotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neural Stem Cell-Preserving Whole Brain RT</title>
          <description>Neural Stem Cell-Preserving Whole Brain Radiotherapy</description>
        </group>
        <group group_id="B2">
          <title>Standard Whole Brain RT</title>
          <description>Standard Whole Brain Radiotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="9.7"/>
                    <measurement group_id="B2" value="52.0" spread="0.0"/>
                    <measurement group_id="B3" value="59.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Increase in the Bi-dimensional Tumor Area for Any of the Tracked Brain Metastases or the Appearance of Any New Brain Metastases on a Follow-up MRI.</title>
        <description>Increase in the bi-dimensional tumor area for any of the tracked brain metastases or the appearance of any new brain metastases on a follow-up MRI.</description>
        <time_frame>12 months after end of radiation therapy</time_frame>
        <population>Study terminated early due to poor accrual</population>
        <group_list>
          <group group_id="O1">
            <title>Neural Stem Cell-Preserving Whole Brain RT</title>
            <description>Neural Stem Cell-Preserving Whole Brain Radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Standard Whole Brain RT</title>
            <description>Standard Whole Brain RT</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in the Bi-dimensional Tumor Area for Any of the Tracked Brain Metastases or the Appearance of Any New Brain Metastases on a Follow-up MRI.</title>
          <description>Increase in the bi-dimensional tumor area for any of the tracked brain metastases or the appearance of any new brain metastases on a follow-up MRI.</description>
          <population>Study terminated early due to poor accrual</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Increase in the Bi-dimensional Tumor Area for Any of the Tracked Brain Metastases or the Appearance of Any New Brain Metastases on a Follow-up MRI.</title>
        <description>Brain metastases bi-dimensional area</description>
        <time_frame>12 months post RT</time_frame>
        <population>Not enough patients were enrolled to allow for any meaningful analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Neural Stem Cell-Preserving Whole Brain RT</title>
            <description>Neural Stem Cell-Preserving Whole Brain Radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Standard Whole Brain RT</title>
            <description>Standard Whole Brain RT</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in the Bi-dimensional Tumor Area for Any of the Tracked Brain Metastases or the Appearance of Any New Brain Metastases on a Follow-up MRI.</title>
          <description>Brain metastases bi-dimensional area</description>
          <population>Not enough patients were enrolled to allow for any meaningful analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Neural Stem Cell-Preserving Whole Brain RT</title>
          <description>Neural Stem Cell-Preserving Whole Brain Radiotherapy</description>
        </group>
        <group group_id="E2">
          <title>Standard Whole Brain RT</title>
          <description>Standard Whole Brain RT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance - New Brain Mets</sub_title>
                <description>Attributed to disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neurology - Other (Disease Progression)</sub_title>
                <description>Attributed to disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial not completed. Insufficient data to analyze.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Martha D. Wellons</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-628-1939</phone>
      <email>mwellons@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

